[
  {
    "ts": null,
    "headline": "Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma",
    "summary": "The global influenza vaccine market is on a growth trajectory, driven by heightened awareness about vaccination's role in preventing contagious diseases like influenza. In light of recent pandemics, flu vaccination demand is surging, projected to climb from USD 8.96 billion in 2024 to USD 13.32 billion by 2030, at a CAGR of 7%. Rising geriatric populations, government support, and public health campaigns fuel this expansion. Dominant market segments include quadrivalent vaccines, inactivated typ",
    "url": "https://finnhub.io/api/news?id=55c7cc77d1fd20de5684daa8ba9a18267a9e8f07b6b81697e00ce172515607a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754576160,
      "headline": "Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma",
      "id": 136248796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global influenza vaccine market is on a growth trajectory, driven by heightened awareness about vaccination's role in preventing contagious diseases like influenza. In light of recent pandemics, flu vaccination demand is surging, projected to climb from USD 8.96 billion in 2024 to USD 13.32 billion by 2030, at a CAGR of 7%. Rising geriatric populations, government support, and public health campaigns fuel this expansion. Dominant market segments include quadrivalent vaccines, inactivated typ",
      "url": "https://finnhub.io/api/news?id=55c7cc77d1fd20de5684daa8ba9a18267a9e8f07b6b81697e00ce172515607a7"
    }
  },
  {
    "ts": null,
    "headline": "United States Vaccines Market Insights and Forecasts 2024 & 2025-2033 | Rising Infectious Disease Burden, Robust Funding and Regulatory Support Accelerate Innovation",
    "summary": "The US vaccines market, valued at $29.5B in 2024, is projected to reach $60B by 2033, at a CAGR of 8.2%. Key growth drivers include rising infectious diseases and biotech advancements. Comprehensive analysis covers market dynamics, regulatory environment, and top players like Pfizer and Merck. U.S. Vaccines Market U.S. Vaccines Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033\" report",
    "url": "https://finnhub.io/api/news?id=a3c949f863a6b4b6fd050851bb0dfe742b06154922c54082d4e792b0073a4c40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754574000,
      "headline": "United States Vaccines Market Insights and Forecasts 2024 & 2025-2033 | Rising Infectious Disease Burden, Robust Funding and Regulatory Support Accelerate Innovation",
      "id": 136266757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The US vaccines market, valued at $29.5B in 2024, is projected to reach $60B by 2033, at a CAGR of 8.2%. Key growth drivers include rising infectious diseases and biotech advancements. Comprehensive analysis covers market dynamics, regulatory environment, and top players like Pfizer and Merck. U.S. Vaccines Market U.S. Vaccines Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033\" report",
      "url": "https://finnhub.io/api/news?id=a3c949f863a6b4b6fd050851bb0dfe742b06154922c54082d4e792b0073a4c40"
    }
  },
  {
    "ts": null,
    "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
    "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
    "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754570460,
      "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
      "id": 136246157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
      "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr’s mRNA funding halt signals “shift in US public health”",
    "summary": "The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.",
    "url": "https://finnhub.io/api/news?id=941ddaff6855a991a20d9423905639cb78835b6465ba4c05e478869f6b2235d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754566494,
      "headline": "RFK Jr’s mRNA funding halt signals “shift in US public health”",
      "id": 136246383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.",
      "url": "https://finnhub.io/api/news?id=941ddaff6855a991a20d9423905639cb78835b6465ba4c05e478869f6b2235d4"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug",
    "summary": "The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new partner.",
    "url": "https://finnhub.io/api/news?id=037b59eb2d0133eb9a4ca8ec95a2e8eeec7da00d221fc60836d101d8b8dcb4d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754566200,
      "headline": "Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug",
      "id": 136266929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new partner.",
      "url": "https://finnhub.io/api/news?id=037b59eb2d0133eb9a4ca8ec95a2e8eeec7da00d221fc60836d101d8b8dcb4d7"
    }
  },
  {
    "ts": null,
    "headline": "This 7% Yielding Stock Just Raised Its Profit Forecast. Is It Time to Buy?",
    "summary": "Meeting its dividend commitment this year should be a breeze, but the path ahead is much harder to predict.",
    "url": "https://finnhub.io/api/news?id=1a402a66bba670f8d7c87ce1a43fefbb451d6638e7897e7e7d8762a9c9703459",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754560620,
      "headline": "This 7% Yielding Stock Just Raised Its Profit Forecast. Is It Time to Buy?",
      "id": 136246384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Meeting its dividend commitment this year should be a breeze, but the path ahead is much harder to predict.",
      "url": "https://finnhub.io/api/news?id=1a402a66bba670f8d7c87ce1a43fefbb451d6638e7897e7e7d8762a9c9703459"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Turnaround Has Truly Started (Earnings Update)",
    "summary": "Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=0f03d520026c614d24ede15271a65097b8b16bee99ce35105cfafaa51cc17238",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754547621,
      "headline": "Pfizer's Turnaround Has Truly Started (Earnings Update)",
      "id": 136245244,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491484031/image_1491484031.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=0f03d520026c614d24ede15271a65097b8b16bee99ce35105cfafaa51cc17238"
    }
  }
]